BioNTech SE (BNTX) News
Follow BioNTech SE (BNTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 37 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
BioNTech-DualityBiologics Phase 3 Breast Cancer Trial Meets Primary Endpoint
The companies reported severe, fatal events in the trial.
EQUITY | Oct 26, 2026, 09:37 AM UTC
L
BioNTech and DualityBio Announce Phase 3 DYNASTY-Breast02 Topline Results
BioNTech and DualityBio announced topline results from the global Phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer.
EQUITY | Oct 26, 2026, 09:03 AM UTC
M
BioNTech Reports Phase 2 Pumitamig Data in Advanced NSCLC
Pumitamig plus docetaxel produced a 36.7% confirmed ORR among 30 evaluable patients and median PFS of 6.9 months among 50 treated, with manageable safety.
EQUITY | Oct 25, 2026, 07:34 AM UTC
M
BioNTech Shares Fall Roughly 7% After BNT113 Trial Miss
BioNTech shares closed down roughly 7% Tuesday after its investigational mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival benefit in a late-stage trial. An analyst lin
EQUITY | Oct 13, 2026, 11:15 PM UTC
M
BioNTech mRNA Cancer Therapy Misses Trial’s First Main Goal
BioNTech said its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. Its US-listed shares were down nearly 3% in early trading.
EQUITY | Oct 13, 2026, 01:41 PM UTC
M
BioNTech Cancer Therapy Misses Main Goal in Head and Neck Trial
BioNTech said its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. Its U.S.-listed shares were down nearly 6% in premarket trad
EARNINGS | Oct 13, 2026, 12:13 PM UTC
M
BioNTech Cancer Drug Fails First Trial Endpoint
BioNTech said its BNT113 immunotherapy, combined with pembrolizumab, did not significantly improve progression-free survival at the first dual primary endpoint in a Phase 2/3 trial.
EQUITY | Oct 13, 2026, 11:21 AM UTC
L
BioNTech updates Phase 2/3 trial of BNT113 cancer immunotherapy
BioNTech provided an update on its Phase 2/3 clinical trial of BNT113, an mRNA cancer immunotherapy candidate for metastatic HPV16-positive head and neck cancer.
EQUITY | Oct 13, 2026, 10:48 AM UTC
H
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh investor interest in vaccine makers, sending several biotechnology and pharmaceutical stocks higher Friday. Moderna, Inc. (NA
LIVE | Oct 09, 2026, 07:11 PM UTC
L
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
By Blake BrittainA federal judge in Delaware on Monday rejected Pfizer NYSE:PFE, BioNTech NASDAQ:BNTX and Moderna's NASDAQ:MRNA requests to dismiss patent lawsuits filed against them by Bayer's XETR:BAYN Monsanto unit ov
REGULATION | Sep 28, 2026, 06:20 PM UTC
L
BioNTech to Proceed With Site Closures After Failing to Find Buyer
By Adria CalatayudBioNTech said it would proceed with the closure of sites after it couldn't reach agreements to sell the facilities."Despite the intensive efforts of all parties involved and a broad-based sales process,
NEWS | Sep 28, 2026, 02:35 PM UTC
L
BioNTech to shutter sites in Germany, Singapore as no buyers emerge
German COVID—19 vaccine maker BioNTech NASDAQ:BNTX said on Monday it would close sites in Germany and Singapore because it failed to find buyers after pivoting away from pandemic-era manufacturing."Despite the best effor
NEWS | Sep 28, 2026, 01:04 PM UTC
H
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.Monday - September 14Tuesday - September
CENTRAL_BANK | Sep 11, 2026, 07:01 PM UTC
M
BMO cuts BioNTech price target to $105 from $128
BMO Capital cut its BioNTech price target to $105.00 per share from $128.00, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 12:21 PM UTC
L
BioNTech Kills a Cancer Trial Roche Helped Build
BioNTech Kills a Cancer Trial Roche Helped Build
EQUITY | Aug 28, 2026, 06:06 PM UTC
L
BNTX stock slips after cancer vaccine trial halt, BMO calls it clear setback
BNTX is on track for its worst day since March following a cancer vaccine trial halt, per TradingView News citing BMO Capital.
EQUITY | Aug 28, 2026, 05:22 PM UTC
M
FDA approves seasonal Covid-19 vaccines from Moderna, Pfizer, BioNTech, Novavax
FDA approved seasonal Covid-19 vaccines from Moderna, Pfizer, BioNTech and Novavax, according to an update.
REGULATION | Aug 28, 2026, 03:26 PM UTC
L
BioNTech cancels midstage colorectal cancer treatment trial
BioNTech has canceled its midstage trial of a colorectal cancer treatment.
EQUITY | Aug 28, 2026, 03:06 PM UTC
L
BioNTech Stock Falls on Cancer Vaccine Setback — Barrons.com
BioNTech Stock Falls on Cancer Vaccine Setback — Barrons.com
EQUITY | Aug 28, 2026, 02:46 PM UTC
M
US FDA approves updated COVID vaccines for 2026-27 season
US FDA approves updated COVID vaccines for the 2026-27 season.
REGULATION | Aug 27, 2026, 09:41 PM UTC
M
FDA approves seasonal Covid-19 vaccines from Moderna, Pfizer, BioNTech
FDA approved seasonal Covid-19 vaccines from Moderna, Pfizer and BioNTech.
REGULATION | Aug 27, 2026, 09:04 PM UTC
M
BNTX gets U.S. FDA approval for XFG-adapted COVID-19 vaccine
Pfizer and BioNTech received U.S. FDA approval for an XFG-adapted COVID-19 vaccine.
REGULATION | Aug 27, 2026, 08:32 PM UTC
L
BNTX briefly breaks yesterday's low, then rebounds
BNTX briefly breaks yesterday's low and bounces back, though it remains down 3.8%; the alert supplies no catalyst or additional magnitude context.
EQUITY | Aug 20, 2026, 01:33 PM UTC
L
BNTX - earlier PR: Biontech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan N
BNTX - earlier PR: Biontech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026; Data Highlights Progress Across Pumitamig (
EQUITY | Aug 20, 2026, 12:59 PM UTC
M
BioNTech highlights lung cancer pipeline ahead of WCLC 2026
BioNTech says it will present first global lung cancer data for pumitamig with elfetabart drozuntecan from a Phase 1/2 trial and updated overall survival data from Phase 3 PRESERVE-003 for gotistobart.
EQUITY | Aug 20, 2026, 09:33 AM UTC
L
BNTX - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel C
BNTX - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
EQUITY | Aug 20, 2026, 09:30 AM UTC
L
Leerink says cancer vaccine win should sustain Merck momentum into fall
Leerink says a cancer vaccine win should sustain Merck momentum into fall, with the note referencing MRNA, BNTX and MRK and supplying no further catalyst details.
EQUITY | Aug 19, 2026, 02:39 PM UTC
H
Moderna jumps 40% after trial results; Merck, BioNTech rise
Moderna is squeezing, now up 40%, while Merck rises 3.4% and BioNTech 3.9% after trial results, with no further catalyst supplied.
EQUITY | Aug 19, 2026, 10:55 AM UTC
L
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est
BioNTech (NASDAQ: BNTX ) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.
EARNINGS | Aug 04, 2026, 10:46 AM UTC
L
BNTX - BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
BNTX - BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
EARNINGS | Aug 04, 2026, 10:45 AM UTC
H
BNTX Names Sobi's Oelkers as Next CEO
BNTX appoints new CEO
EQUITY | Aug 03, 2026, 10:24 AM UTC
H
BioNTech Appoints Guido Oelkers as Next CEO
BioNTech appoints Guido Oelkers as CEO
EQUITY | Aug 03, 2026, 10:04 AM UTC
H
BioNTech Appoints Guido Oelkers CEO
BioNTech names new CEO
EQUITY | Aug 03, 2026, 09:00 AM UTC
H
European Union: Pfizer, BioNTech COVID-19 Vaccine Authorized
Pfizer, BioNTech COVID-19 vaccine authorized
EQUITY | Jul 29, 2026, 08:30 PM UTC
H
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out'
Rep. Thomas Massie (R-Ky.) questioned Vice President JD Vance ‘s silence after the Trump administration established billions for Pfizer Inc. ‘s (NYSE: PFE ) COVID-19 vaccine contracts for 2026 and 2027. On Sunday, Massie
GEOPOLITICS | Jul 27, 2026, 12:01 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC